Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Sev-eral biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD. This technical review systematically searched and identified the current evidence, synthesized it using meta-analytic methodology, appraised its quality, and concisely presented it, thus forming the basis for developing clinical practice recommendations on the use of biologic treatments in adult patients with CD. (c) 2023 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.

Automated summary

This article systematically searched and synthesized current evidence on the use of biologic treatments in adult patients with Crohn's disease, and provided clinical practice recommendations based on the evaluated evidence.